<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns="http://purl.org/rss/1.0/"><channel rdf:about="http://www.phytomedicinejournal.com/?rss=yes"><title>Phytomedicine</title><description>Phytomedicine RSS feed: Current Issue.    
 Phytomedicine  is published to attract and disseminate innovative and expert findings 
in the fields of phytopharmacology, phytotherapy 
and phytotoxicology, as a reference 
source for researchers in these fields, and with the aim to set international 
standards in their 
methodology. The journal publishes research results on phytotherapy 
(clinical trials), phytopharmacology, pharmacognosy, standardization 
and phytotoxicology, 
obtained with plant extracts as well as isolated compounds from these extracts 
and phytopharmaceuticals. Phytomedicine 
is targeted towards papers of a practical 
nature. The papers published in this journal are also useful to drug regulatory 
authorities 
in deciding whether to approve certain phytomedicines or not. Phytomedicine 
consists of the following sections: Case reports, Pharmacological 
and molecularbiological 
studies, Screening studies (only when focused on plant extracts or isolated compounds 
with extraordinary activities, 
Chemical structure - activity studies, Chemical 
analysis and standardization of plant drugs and phytopharmaceuticals, Reviews 
(by invitation).

 For more information, go to    http://www.elsevier.de/phymed 
   </description><link>http://www.phytomedicinejournal.com/?rss=yes</link><dc:publisher>Elsevier Inc.</dc:publisher><dc:language>en</dc:language><dc:rights> © 2011 Published by Elsevier Inc. All rights reserved. </dc:rights><prism:publicationName>Phytomedicine</prism:publicationName><prism:issn>0944-7113</prism:issn><prism:volume>19</prism:volume><prism:number>2</prism:number><prism:publicationDate>15 January 2012</prism:publicationDate><prism:copyright> © 2011 Published by Elsevier Inc. All rights reserved. </prism:copyright><prism:rightsAgent>healthpermissions@elsevier.com</prism:rightsAgent><items><rdf:Seq><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS094471131100571X/abstract?rss=yes"/><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS0944711311002613/abstract?rss=yes"/><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS0944711311002650/abstract?rss=yes"/><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS0944711311002364/abstract?rss=yes"/><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS0944711311002674/abstract?rss=yes"/><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS0944711311003229/abstract?rss=yes"/><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS0944711311002601/abstract?rss=yes"/><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS0944711311002352/abstract?rss=yes"/><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS0944711311002005/abstract?rss=yes"/><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS0944711311002339/abstract?rss=yes"/><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS0944711311002686/abstract?rss=yes"/><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS0944711311002261/abstract?rss=yes"/><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS0944711311003230/abstract?rss=yes"/><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS0944711311005320/abstract?rss=yes"/></rdf:Seq></items></channel><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS094471131100571X/abstract?rss=yes"><title>Editorial Board</title><link>http://www.phytomedicinejournal.com/article/PIIS094471131100571X/abstract?rss=yes</link><description></description><dc:title>Editorial Board</dc:title><dc:creator></dc:creator><dc:identifier>10.1016/S0944-7113(11)00571-X</dc:identifier><dc:source>Phytomedicine 19, 2 (2012)</dc:source><dc:date>2012-01-15</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2012-01-15</prism:publicationDate><prism:volume>19</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S0944-7113(11)X0014-4</prism:issueIdentifier><prism:section></prism:section><prism:startingPage>CO2</prism:startingPage><prism:endingPage>CO2</prism:endingPage></item><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS0944711311002613/abstract?rss=yes"><title>Danshen–Gegen decoction protects against hypoxia/reoxygenation-induced apoptosis by inhibiting mitochondrial permeability transition via the redox-sensitive ERK/Nrf2 and PKCɛ/mKATP pathways in H9c2 cardiomyocytes</title><link>http://www.phytomedicinejournal.com/article/PIIS0944711311002613/abstract?rss=yes</link><description>Abstract: Danshen–Gegen (DG) Decoction, an herbal formulation containing Radix Salviae miltiorrhizae and Radix Puerariae lobatae, has been used for the treatment of coronary artery disease in Chinese medicine. In the present study, the involvement of ERK- and PKCɛ-mediated pathways in the cytoprotection against apoptosis afforded by DG pretreatment was investigated in H9c2 cardiomyocytes. Pretreatment with a methanol extract of aqueous DG decoction protected against hypoxia/reoxygenation-induced apoptosis in H9c2 cardiomyocytes. The cytoprotection was associated the enhancement of cellular reduced glutathione and a reduced sensitivity to Ca2+-induced mitochondrial permeability transition. DG extract increased the production of cytochrome P-450 (CYP)-dependent reactive oxygen species (ROS) in H9c2 cardiomyocytes, which was accompanied by the concomitant activation of ERK1/2 and PKCɛ. The DG-induced ERK1/2 activation was followed by the translocation of Nrf2 from the cytosol to the mitochondria accompanied by an increase in the expression of glutathione-related antioxidant proteins. In addition, the increased expression of hemeoxygenase-1 was associated with the activation of Akt and BAD, indicative of anti-apoptotic activity. In conclusion, DG treatment activated both ERK/Nrf2 and PKCɛ pathways, presumably by ROS arising from CYP-catalyzed processes, with resultant inhibition of hypoxia/reoxygenation-induced apoptosis immediately after DG treatment or even after an extended time interval following DG treatment.</description><dc:title>Danshen–Gegen decoction protects against hypoxia/reoxygenation-induced apoptosis by inhibiting mitochondrial permeability transition via the redox-sensitive ERK/Nrf2 and PKCɛ/mKATP pathways in H9c2 cardiomyocytes</dc:title><dc:creator>Po Yee Chiu, Hoi Yan Leung, Pou Kuan Leong, Na Chen, Limin Zhou, Zhong Zuo, Philip Y. Lam, Kam Ming Ko</dc:creator><dc:identifier>10.1016/j.phymed.2011.07.002</dc:identifier><dc:source>Phytomedicine 19, 2 (2012)</dc:source><dc:date>2011-09-07</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2011-09-07</prism:publicationDate><prism:volume>19</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S0944-7113(11)X0014-4</prism:issueIdentifier><prism:section>Cardiovascular System</prism:section><prism:startingPage>99</prism:startingPage><prism:endingPage>110</prism:endingPage></item><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS0944711311002650/abstract?rss=yes"><title>In vitro anti-influenza virus activity of a cardiotonic glycoside from Adenium obesum (Forssk.)</title><link>http://www.phytomedicinejournal.com/article/PIIS0944711311002650/abstract?rss=yes</link><description>Abstract: Methanolic extracts of six Saudi plants were screened for their in vitro antiviral activity using influenza virus A/PR/8/34 (H1N1) and MDCK cells in an MTT assay. The results indicated that the extracts of Adeniumobesum and Tephorosianubica possessed antiviral activity (99.3 and 93.3% inhibition at the concentration of 10μg/ml, respectively). Based on these results A. obesum was selected for further study by applying bioactivity-guided fractionation to isolate its antiviral principle. The antiviral principle was isolated from the chloroform fraction through solvent fractionation, combined open liquid chromatography and HPLC. The isolated active compound A was identified as oleandrigenin-β-d-glucosyl (1→4)-β-d-digitalose, on the basis of its spectral analysis (MS, 1D and 2D NMR). The isolated glycoside showed reduction of virus titre by 69.3% inhibition at concentration of 1μg/ml (IC50=0.86μg/ml).</description><dc:title>In vitro anti-influenza virus activity of a cardiotonic glycoside from Adenium obesum (Forssk.)</dc:title><dc:creator>Hiroaki Kiyohara, Chikara Ichino, Yuka Kawamura, Takayuki Nagai, Noriko Sato, Haruki Yamada, Maha M. Salama, Essam Abdel-Sattar</dc:creator><dc:identifier>10.1016/j.phymed.2011.07.004</dc:identifier><dc:source>Phytomedicine 19, 2 (2012)</dc:source><dc:date>2011-09-07</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2011-09-07</prism:publicationDate><prism:volume>19</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S0944-7113(11)X0014-4</prism:issueIdentifier><prism:section>Infections</prism:section><prism:startingPage>111</prism:startingPage><prism:endingPage>114</prism:endingPage></item><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS0944711311002364/abstract?rss=yes"><title>Kalanchoe pinnata inhibits mast cell activation and prevents allergic airway disease</title><link>http://www.phytomedicinejournal.com/article/PIIS0944711311002364/abstract?rss=yes</link><description>Abstract: Aqueous extract of Kalanchoe pinnata (Kp) have been found effective in models to reduce acute anaphylactic reactions. In the present study, we investigate the effect of Kp and the flavonoid quercetin (QE) and quercitrin (QI) on mast cell activation in vitro and in a model of allergic airway disease in vivo. Treatment with Kp and QE in vitro inhibited degranulation and cytokine production of bone marrow-derived mast cells following IgE/FcɛRI crosslinking, whereas treatment with QI had no effect. Similarly, in vivo treatment with Kp and QE decreased development of airway hyperresponsiveness, airway inflammation, goblet cell metaplasia and production of IL-5, IL-13 and TNF. In contrast, treatment with QI had no effect on these parameters. These findings demonstrate that treatment with Kp or QE is effective in treatment of allergic airway disease, providing new insights to the immunomodulatory functions of this plant.</description><dc:title>Kalanchoe pinnata inhibits mast cell activation and prevents allergic airway disease</dc:title><dc:creator>E.A. Cruz, S. Reuter, H. Martin, N. Dehzad, M.F. Muzitano, S.S. Costa, B. Rossi-Bergmann, R. Buhl, M. Stassen, C. Taube</dc:creator><dc:identifier>10.1016/j.phymed.2011.06.030</dc:identifier><dc:source>Phytomedicine 19, 2 (2012)</dc:source><dc:date>2011-08-01</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2011-08-01</prism:publicationDate><prism:volume>19</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S0944-7113(11)X0014-4</prism:issueIdentifier><prism:section>Inflammation</prism:section><prism:startingPage>115</prism:startingPage><prism:endingPage>121</prism:endingPage></item><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS0944711311002674/abstract?rss=yes"><title>Modified Wu-Zi-Yan-Zong prescription, a traditional Chinese polyherbal formula, suppresses lipopolysaccharide-induced neuroinflammatory processes in rat astrocytes via NF-κB and JNK/p38 MAPK signaling pathways</title><link>http://www.phytomedicinejournal.com/article/PIIS0944711311002674/abstract?rss=yes</link><description>Abstract: Neuroinflammation plays an important role in several neurodegenerative diseases. In this study, we investigated the anti-inflammatory properties of modified Wu-Zi-Yan-Zong prescription (MWP), a traditional Chinese polyherbal formula, in primary cultured rat astrocytes treated with lipopolysaccharide (LPS). The results showed that MWP significantly inhibited release of nitric oxide (NO) and prostaglandin E (PGE), as well as expressions of inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2 in LPS-induced rat astrocytes. Mechanism study indicated that MWP significantly inhibited nuclear factor-kappa B (NF-κB) inflammatory signaling pathway through attenuating inhibitor of nuclear factor-κB (IκB) degradation and down-regulating IκB kinases (IKKs) phosphorylation level. Moreover, MWP also decreased c-Jun NH2-terminal kinase (JNK)/p38 mitogen-activated protein kinase (MAPK) phosphorylation, which play an important role in the induction of proinflammatory gene expressions. At last, MWP protected neurons from LPS-activated astrocytes in neuron–astrocyte co-culture system. Taken together, our results suggest that MWP may act to suppress neuroinflammatory response in LPS-stimulated rat astrocytes via NF-κB and JNK/p38 MAPK signaling cascades, and MWP may be a useful agent for prevention and treatment of neuroinflammatory disease.</description><dc:title>Modified Wu-Zi-Yan-Zong prescription, a traditional Chinese polyherbal formula, suppresses lipopolysaccharide-induced neuroinflammatory processes in rat astrocytes via NF-κB and JNK/p38 MAPK signaling pathways</dc:title><dc:creator>Ke-Wu Zeng, Tai Zhang, Hong Fu, Geng-Xin Liu, Xue-Mei Wang</dc:creator><dc:identifier>10.1016/j.phymed.2011.08.003</dc:identifier><dc:source>Phytomedicine 19, 2 (2012)</dc:source><dc:date>2011-09-07</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2011-09-07</prism:publicationDate><prism:volume>19</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S0944-7113(11)X0014-4</prism:issueIdentifier><prism:section>Inflammation</prism:section><prism:startingPage>122</prism:startingPage><prism:endingPage>129</prism:endingPage></item><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS0944711311003229/abstract?rss=yes"><title>Bupleurum chinense DC polysaccharides attenuates lipopolysaccharide-induced acute lung injury in mice</title><link>http://www.phytomedicinejournal.com/article/PIIS0944711311003229/abstract?rss=yes</link><description>Abstract: Bupleurum chinense DC had hepato-protective, anti-inflammatory, antipyretic, analgesic, and immunomodulatory effect in traditional Chinese medicine. This study was to determine whether the crude polysaccharides isolated from the roots of Bupleurum chinense DC (BCPs) attenuated lipopolysaccharide (LPS)-induced acute lung injury in mice. Mice were challenged with LPS intratracheally 2h before BCPs (20, 40 and 80mg/kg) administration. The bronchoalveolar lavage fluid (BALF) was collected 24h after LPS challenge. Treatment with BCPs reduced lung wet-to-dry weight ratio. The elevated number of total cells and protein concentration in BALF was reduced. The increased level of myeloperoxidase (MPO), tumor necrosis factor-α (TNF-α) in BALF, and serum nitric oxide (NO) were also inhibited. BCPs significantly attenuated lung injury with improved lung morphology and reduced complement deposition. These results suggested that the effect of BCPs against ALI might be related with its inhibitory effect on excessive activation of complement and on the production of proinflammatory mediators.</description><dc:title>Bupleurum chinense DC polysaccharides attenuates lipopolysaccharide-induced acute lung injury in mice</dc:title><dc:creator>Jun-yun Xie, Hong-ye Di, Hong Li, Xiao-qin Cheng, Yun-yi Zhang, Dao-feng Chen</dc:creator><dc:identifier>10.1016/j.phymed.2011.08.057</dc:identifier><dc:source>Phytomedicine 19, 2 (2012)</dc:source><dc:date>2011-11-24</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2011-11-24</prism:publicationDate><prism:volume>19</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S0944-7113(11)X0014-4</prism:issueIdentifier><prism:section>Inflammation</prism:section><prism:startingPage>130</prism:startingPage><prism:endingPage>137</prism:endingPage></item><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS0944711311002601/abstract?rss=yes"><title>Eurycomanone suppresses expression of lung cancer cell tumor markers, prohibitin, annexin 1 and endoplasmic reticulum protein 28</title><link>http://www.phytomedicinejournal.com/article/PIIS0944711311002601/abstract?rss=yes</link><description>Abstract: Bioactive compounds from the medicinal plant, Eurycoma longifolia Jack have been shown to promote anti-proliferative effects on various cancer cell lines. Here we examined the effects of purified eurycomanone, a quassinoid found in Eurycoma longifolia Jack extract, on the expression of selected genes of the A549 lung cancer cells. Eurycomanone inhibited A549 lung cancer cell proliferation in a dose-dependent manner at concentrations ranging from 5 to 20μg/ml. The concentration that inhibited 50% of cell growth (GI50) was 5.1μg/ml. The anti-proliferative effects were not fully reversible following the removal of eurycomanone, in which 30% of cell inhibition still remained (p&lt;0.0001, T-test). At 8μg/ml (GI70), eurycomanone suppressed anchorage-independent growth of A549 cells by &gt;25% (p&lt;0.05, T-test, n=8) as determined using soft agar colony formation assay. Cisplatin, a chemotherapy drug used for the treatment of non small cell lung cancer on the other hand, inhibited A549 cells proliferation at concentrations ranging from 0.2μg/ml to 15μg/ml with a GI50 of 0.58μg/ml. The treatment with eurycomanone reduced the abundance expression of the lung cancer markers, heterogeneous nuclear ribonucleoprotein (hnRNP) A2/B1, p53 tumor suppressor protein and other cancer-associated genes including prohibitin (PHB), annexin 1 (ANX1) and endoplasmic reticulum protein 28 (ERp28) but not the house keeping genes. The mRNA expressions of all genes with the exception of PHB were significantly downregulated, 72h after treatment (p&lt;0.05, T-test, n=9). These findings suggest that eurycomanone at viable therapeutic concentrations of 5–20μg/ml exhibited significant anti-proliferative and anti-clonogenic cell growth effects on A549 lung cancer cells. The treatment also resulted in suppression of the lung cancer cell tumor markers and several known cancer cell growth-associated genes.</description><dc:title>Eurycomanone suppresses expression of lung cancer cell tumor markers, prohibitin, annexin 1 and endoplasmic reticulum protein 28</dc:title><dc:creator>Pooi-Fong Wong, Wei-Fun Cheong, Meng-Hooi Shu, Chin-Hoe Teh, Kit-Lam Chan, Sazaly AbuBakar</dc:creator><dc:identifier>10.1016/j.phymed.2011.07.001</dc:identifier><dc:source>Phytomedicine 19, 2 (2012)</dc:source><dc:date>2011-09-07</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2011-09-07</prism:publicationDate><prism:volume>19</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S0944-7113(11)X0014-4</prism:issueIdentifier><prism:section>Oncology and Hematology</prism:section><prism:startingPage>138</prism:startingPage><prism:endingPage>144</prism:endingPage></item><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS0944711311002352/abstract?rss=yes"><title>Antidepressant-like effect of hyperoside isolated from Apocynum venetum leaves: Possible cellular mechanisms</title><link>http://www.phytomedicinejournal.com/article/PIIS0944711311002352/abstract?rss=yes</link><description>Graphical abstract: We studied the possible cellular mechanisms of hyperoside isolated from Apocynum venetum leaves in corticosterone-induced neurotoxicity, using PC12 cells as a suitable in vitro model of depression. Cell viability was quantitated by 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. The release amount of lactic dehydrogenase (LDH) and intracellular Ca2+ concentration were measured using kit, and transcript abundances of brain-derived neurotrophic factor (BDNF) and cAMP response element binding protein (CREB) were determined by real-time RT-PCR.Abstract: In the present work, we studied the possible cellular mechanisms of hyperoside isolated from Apocynum venetum leaves in corticosterone-induced neurotoxicity, using PC12 cells as a suitable in vitro model of depression. Cell viability was quantitated by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. The release amount of lactic dehydrogenase (LDH) and intracellular Ca2+ concentration were measured using kit and transcript abundances of brain-derived neurotrophic factor (BDNF) and cAMP response element binding protein (CREB) were determined by real-time RT-PCR.The results of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and lactic dehydrogenase (LDH) assays showed that 2.5, 5 and 10μg/ml hyperoside or 10μM fluoxetine (FLU) protected PC12 cells from the lesion induced by a 48h treatment with 10μM corticosterone. Fura-2/AM (acetoxymethyl ester) assays showed that 2.5, 5 and 10μg/ml hyperoside or 10μM FLU attenuated the intracellular Ca2+ overloading in PC12 cells induced by corticosterone. The transcript abundance of BDNF and CREB in PC12 cells was elevated upon hyperoside treatment. These results suggest that the possible cellular mechanisms of hyperoside antidepressant-like effect is a cytoprotective action related to elevation the expression of BDNF and CREB through the signal pathway AC–cAMP–CREB.</description><dc:title>Antidepressant-like effect of hyperoside isolated from Apocynum venetum leaves: Possible cellular mechanisms</dc:title><dc:creator>Meizhu Zheng, Chunming Liu, Fengguang Pan, Dongfang Shi, Yuchi Zhang</dc:creator><dc:identifier>10.1016/j.phymed.2011.06.029</dc:identifier><dc:source>Phytomedicine 19, 2 (2012)</dc:source><dc:date>2011-08-01</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2011-08-01</prism:publicationDate><prism:volume>19</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S0944-7113(11)X0014-4</prism:issueIdentifier><prism:section>Neurology</prism:section><prism:startingPage>145</prism:startingPage><prism:endingPage>149</prism:endingPage></item><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS0944711311002005/abstract?rss=yes"><title>Neuroprotection of the leaf and stem of Vitis amurensis and their active compounds against ischemic brain damage in rats and excitotoxicity in cultured neurons</title><link>http://www.phytomedicinejournal.com/article/PIIS0944711311002005/abstract?rss=yes</link><description>Abstract: Vitis amurensis (Vitaceae) has been reported to have anti-oxidant and anti-inflammatory activities. The present study investigated a methanol extract from the leaf and stem of V. amurensis for neuroprotective effects on cerebral ischemic damage in rats and on excitotoxicity induced by glutamate in cultured rat cortical neurons. Transient focal cerebral ischemia was induced by 2h middle cerebral artery occlusion followed by 24h reperfusion (MCAO/reperfusion) in rats. Orally administered V. amurensis (25–100mg/kg) reduced MCAO/reperfusion-induced infarct and edema formation, neurological deficits, and neuronal death. Depletion of glutathione (GSH) level and lipid peroxidation induced by MCAO/reperfusion was inhibited by administration of V. amurensis. The increase of phosphorylated mitogen-activated protein kinases (MAPKs), cyclooxygenase-2 (COX-2), and pro-apoptotic proteins and the decrease of anti-apoptotic protein in MCAO/reperfusion rats were significantly inhibited by treatment with V. amurensis. Exposure of cultured cortical neurons to 500μM glutamate for 12h induced neuronal cell death. V. amurensis (1–50μg/ml) and (+)-ampelopsin A, γ-2-viniferin, and trans-ɛ-viniferin isolated from the leaf and stem of V. amurensis inhibited glutamate-induced neuronal death, the elevation of intracellular calcium ([Ca2+]i), the generation of reactive oxygen species (ROS), and changes of apoptosis-related proteins in cultured cortical neurons, suggesting that the neuroprotective effect of V. amurensis may be partially attributed to these compounds. These results suggest that the neuroprotective effect of V. amurensis against focal cerebral ischemic injury might be due to its anti-apoptotic effect, resulting from anti-excitotoxic, anti-oxidative, and anti-inflammatory effects and that the leaf and stem of V. amurensis have possible therapeutic roles for preventing neurodegeneration in stroke.</description><dc:title>Neuroprotection of the leaf and stem of Vitis amurensis and their active compounds against ischemic brain damage in rats and excitotoxicity in cultured neurons</dc:title><dc:creator>Joo Youn Kim, Ha Yeon Jeong, Hong Kyu Lee, SeungHwan Kim, Bang Yeon Hwang, KiHwan Bae, Yeon Hee Seong</dc:creator><dc:identifier>10.1016/j.phymed.2011.06.015</dc:identifier><dc:source>Phytomedicine 19, 2 (2012)</dc:source><dc:date>2011-07-21</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2011-07-21</prism:publicationDate><prism:volume>19</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S0944-7113(11)X0014-4</prism:issueIdentifier><prism:section>Neurology</prism:section><prism:startingPage>150</prism:startingPage><prism:endingPage>159</prism:endingPage></item><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS0944711311002339/abstract?rss=yes"><title>A new approach to enhance oral bioavailability of Silybum Marianum dry extract: Association of mechanochemical activation and spray congealing</title><link>http://www.phytomedicinejournal.com/article/PIIS0944711311002339/abstract?rss=yes</link><description>Graphical abstract: The combination of mechanochemical activation and spray congealing produces a delivery system with enhanced oral bioavailability of main flavolignans of Silybum Marianum dry extract, Silybin A and B.Abstract: The aim of the work was to produce a delivery system for Silybum Marianum dry extract with enhanced oral bioavailability by combining two technologies (mechanochemical activation and spray congealing). Initially, the active was coground with sodium croscarmellose in a planetary mill in order to reach an activated state more prone to dissolution. DSC, XRD, FT-IR and LD analyses showed the formation of nanosized particles of dry extract, with reduced degree of crystallinity of the main crystalline flavolignans (silybine A and B). Then, microparticles containing the activated coground and, as comparison, the corresponding physical mixture of extract and polymer and the dry extract alone were produced by spray congealing technology using Gelucire® 50/13 as a hydrophilic low m.p. carrier. Microparticles containing the activated coground were produced spherical in shape, achieved satisfactory yield and high encapsulation efficiency. These microparticles, in addition to a favourable in vitro solubilisation kinetic, in a preliminary in vivo study in five rats demonstrated their ability to improve very significantly the oral bioavailability of the main flavolignans of Silybum Marianum dry extract (silybin A and B). These results suggested that the association of mechanochemical activation and spray congealing could be considered an innovative and very useful approach to the oral delivery of Silybum Marianum. Furthermore, for the first time the possibility of successfully applying the spray congealing technology for the preparation of a herbal drug delivery system was shown.</description><dc:title>A new approach to enhance oral bioavailability of Silybum Marianum dry extract: Association of mechanochemical activation and spray congealing</dc:title><dc:creator>N. Passerini, B. Perissutti, B. Albertini, E. Franceschinis, D. Lenaz, D. Hasa, I. Locatelli, D. Voinovich</dc:creator><dc:identifier>10.1016/j.phymed.2011.06.027</dc:identifier><dc:source>Phytomedicine 19, 2 (2012)</dc:source><dc:date>2011-08-01</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2011-08-01</prism:publicationDate><prism:volume>19</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S0944-7113(11)X0014-4</prism:issueIdentifier><prism:section>Indication-Oriented Research</prism:section><prism:startingPage>160</prism:startingPage><prism:endingPage>168</prism:endingPage></item><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS0944711311002686/abstract?rss=yes"><title>Tanshinone I increases CYP1A2 protein expression and enzyme activity in primary rat hepatocytes</title><link>http://www.phytomedicinejournal.com/article/PIIS0944711311002686/abstract?rss=yes</link><description>Abstract: This study investigated the effects of Danshen and its active ingredients on the protein expression and enzymatic activity of CYP1A2 in primary rat hepatocytes. The ethanolic extract of Danshen roots (containing mainly tanshinones) inhibited CYP1A2-catalyzed phenacetin O-deethylation (IC50=24.6μg/ml) in primary rat hepatocytes while the water extract containing mainly salvianolic acid B and danshenshu had no effect. Individual tanshinones such as cryptotanshinone, dihydrotanshinone, tanshinone IIA inhibited the CYP1A2-mediated metabolism with IC50 values at 12.9, 17.4 and 31.9μM, respectively. After 4-day treatment of the rat hepatocytes, the ethanolic extract of Danshen and tanshinone I increased rat CYP1A2 activity by 6.8- and 5.2-fold, respectively, with a concomitant up-regulation of CYP1A2 protein level by 13.5- and 6.5-fold, respectively. CYP1A2 induction correlated with the up-regulation of mRNA level of aryl hydrocarbon receptor (AhR), which suggested a positive feedback mechanism of tanshinone I-mediated CYP1A2 induction. A formulated Danshen pill (containing mainly danshensu and salvianolic acid B and the tanshinones) up-regulated CYP1A2 protein expression and enzyme activity, but danshensu and salvianolic acid B, when used individually, did not affect CYP1A2 activity. This study was the first report on the Janus action of the tanshinones on rat CYP1A2 activity.</description><dc:title>Tanshinone I increases CYP1A2 protein expression and enzyme activity in primary rat hepatocytes</dc:title><dc:creator>Wayne Y.W. Lee, Xuelin Zhou, Penelope M.Y. Or, Yiu Wa Kwan, John H.K. Yeung</dc:creator><dc:identifier>10.1016/j.phymed.2011.07.006</dc:identifier><dc:source>Phytomedicine 19, 2 (2012)</dc:source><dc:date>2011-09-07</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2011-09-07</prism:publicationDate><prism:volume>19</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S0944-7113(11)X0014-4</prism:issueIdentifier><prism:section>Indication-Oriented Research</prism:section><prism:startingPage>169</prism:startingPage><prism:endingPage>176</prism:endingPage></item><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS0944711311002261/abstract?rss=yes"><title>Ginkgo biloba extract attenuates warfarin-mediated anticoagulation through induction of hepatic cytochrome P450 enzymes by bilobalide in mice</title><link>http://www.phytomedicinejournal.com/article/PIIS0944711311002261/abstract?rss=yes</link><description>Abstract: Ginkgo biloba extract (GBE) is a popular herbal ingredient used worldwide, but it is reported to induce bleeding as a serious adverse event. In this study we examined whether GBE induced spontaneous bleeding or accelerated warfarin anticoagulation via herb–drug interaction. Mice were given GBE or various active components of GBE orally for 5 days and blood coagulation parameters and hepatic cytochrome P450 enzymes (CYPs) were measured. Mice also received warfarin (racemate, (S)- or (R)-enantiomer) for the last 3 days of the 5-day regimen to examine GBE–warfarin interactions. Neither GBE (up to 1000mg/kg) nor ginkgolide B (up to 140mg/kg), a platelet-activating factor antagonist, influenced blood coagulation parameters. In contrast, GBE attenuated the anticoagulant action of warfarin. Bilobalide, a component of GBE that markedly induced hepatic CYPs including (S)-warfarin hydroxylase, showed similar effects. For (S)-warfarin, the anticoagulation action and the interaction with GBE was clear, while the influence on metabolism was greater for (R)-warfarin than for (S)-warfarin, which corresponded to the CYP types induced by GBE. These results suggest that GBE and ginkgolide B have no influence on blood coagulation in vivo, and that GBE attenuates the anticoagulation action of warfarin via induction of hepatic CYPs by bilobalide.</description><dc:title>Ginkgo biloba extract attenuates warfarin-mediated anticoagulation through induction of hepatic cytochrome P450 enzymes by bilobalide in mice</dc:title><dc:creator>Yuko Taki, Kaori Yokotani, Shizuo Yamada, Kazumasa Shinozuka, Yoko Kubota, Yasuo Watanabe, Keizo Umegaki</dc:creator><dc:identifier>10.1016/j.phymed.2011.06.020</dc:identifier><dc:source>Phytomedicine 19, 2 (2012)</dc:source><dc:date>2011-08-01</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2011-08-01</prism:publicationDate><prism:volume>19</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S0944-7113(11)X0014-4</prism:issueIdentifier><prism:section>Indication-Oriented Research</prism:section><prism:startingPage>177</prism:startingPage><prism:endingPage>182</prism:endingPage></item><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS0944711311003230/abstract?rss=yes"><title>Proteomic analysis of the molecular response of Raji cells to maslinic acid treatment</title><link>http://www.phytomedicinejournal.com/article/PIIS0944711311003230/abstract?rss=yes</link><description>Abstract: Maslinic acid, a natural pentacyclic triterpene has been shown to inhibit growth and induce apoptosis in some tumour cell lines. We studied the molecular response of Raji cells towards maslinic acid treatment. A proteomics approach was employed to identify the target proteins. Seventeen differentially expressed proteins including those involved in DNA replication, microtubule filament assembly, nucleo-cytoplasmic trafficking, cell signaling, energy metabolism and cytoskeletal organization were identified by MALDI TOF-TOF MS. The down-regulation of stathmin, Ran GTPase activating protein-1 (RanBP1), and microtubule associated protein RP/EB family member 1 (EB1) were confirmed by Western blotting. The study of the effect of maslinic acid on Raji cell cycle regulation showed that it induced a G1 cell cycle arrest. The differential proteomic changes in maslinic acid-treated Raji cells demonstrated that it also inhibited expression of dUTPase and stathmin which are known to induce early S and G2 cell cycle arrests. The mechanism of maslinic acid-induced cell cycle arrest may be mediated by inhibiting cyclin D1 expression and enhancing the levels of cell cycle-dependent kinase (CDK) inhibitor p21 protein. Maslinic acid suppressed nuclear factor-kappa B (NF-κB) activity which is known to stimulate expression of anti-apoptotic and cell cycle regulatory gene products. These results suggest that maslinic acid affects multiple signaling molecules and inhibits fundamental pathways regulating cell growth and survival in Raji cells.</description><dc:title>Proteomic analysis of the molecular response of Raji cells to maslinic acid treatment</dc:title><dc:creator>W.H. Yap, K.S. Khoo, S.H. Lim, C.C. Yeo, Y.M. Lim</dc:creator><dc:identifier>10.1016/j.phymed.2011.08.058</dc:identifier><dc:source>Phytomedicine 19, 2 (2012)</dc:source><dc:date>2011-09-07</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2011-09-07</prism:publicationDate><prism:volume>19</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S0944-7113(11)X0014-4</prism:issueIdentifier><prism:section>Indication-Oriented Research</prism:section><prism:startingPage>183</prism:startingPage><prism:endingPage>191</prism:endingPage></item><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS0944711311005320/abstract?rss=yes"><title></title><link>http://www.phytomedicinejournal.com/article/PIIS0944711311005320/abstract?rss=yes</link><description>The second revision of Tyler's Herbs of Choice: The Therapeutic Use of Phytomedicinals gives an update of the most useful and commonly encountered phytomedicinals today. Originally authored by Professor Varro E. Tyler, Dr. Dennis V.C. Awang becomes the curator of this book.</description><dc:title></dc:title><dc:creator>Ellie Jhun, Z. Jim Wang</dc:creator><dc:identifier>10.1016/j.phymed.2011.11.007</dc:identifier><dc:source>Phytomedicine 19, 2 (2012)</dc:source><dc:date>2011-12-08</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2011-12-08</prism:publicationDate><prism:volume>19</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S0944-7113(11)X0014-4</prism:issueIdentifier><prism:section>Book Review</prism:section><prism:startingPage>192</prism:startingPage><prism:endingPage>192</prism:endingPage></item></rdf:RDF>
